Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 03, 2023 4:33pm
158 Views
Post# 35201555

RE:Song of 2023

RE:Song of 2023Agree their plans must be realistic and very clear. Have to believe they didn't have a very fun holiday and were burning the candle most nights.  Let's first get a confirmation on a decent last year for sales, which they should have in hand.  Then an idea of what they can work with next year that's realistic.  I have to assume much more of nexts years growth will be available down the income statement.  Then realistic path to breakeven and profits over next 2 years to support a path toward $2 and $3, from which they can raise some money if need be.

Equally important is what Marsolais and his cancer team learned and what they're theorizing on what seems to be working and what's not and why changes may help get from a few responses to many responses that are deeper within the two-three scan time frame. If it's the toxin, talk about it --if it's the target or peptide, talk about what they're theorizing and can guess at.  It it's the toxin that can be dealt with. If the target just isn't powerful or increases human issues, that's another issue.  The Univ Gotemburg guys are also banking on sort overexpression being heaviest on the tumors so they can disrupt the stem cells there. Would be interesting if they've talked with other Sort1 researchers that have written many papers on it's validity as a target in humans. Have to think they would have also thought about the optical, tissue and neuropathy issues as well.   Let's hope we get some insights.  At worse, they'll have to talk about it in Feb report but have to think they'll have at least one of their plans worked out sooner --either financial strategy or trial restart strategy. 

SABBOBCAT wrote: My recommendation for TH management's song of 2023 is Trooper's 1977 hit "We're here for a good time". 

It's all about seizing the opportunity, yet acknowdges thay not everyday will be a good one. Shareholders are here for a good time and to this point it looks like most are sticking it out through the rainy recent days. Now management needs to realize that we can't all be here for a long time, so let's get on with it and deliver on what they can. 


<< Previous
Bullboard Posts
Next >>